Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Has $7.37 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 78.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 53,954 shares of the company’s stock after selling 193,089 shares during the period. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings in Neurocrine Biosciences were worth $7,365,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Neurocrine Biosciences by 19.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,070,096 shares of the company’s stock worth $146,068,000 after buying an additional 175,879 shares during the last quarter. Worldquant Millennium Advisors LLC boosted its holdings in Neurocrine Biosciences by 44.1% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 154,852 shares of the company’s stock valued at $21,137,000 after acquiring an additional 47,370 shares during the period. Triglav Skladi D.O.O. bought a new stake in Neurocrine Biosciences during the fourth quarter valued at about $1,502,000. Teza Capital Management LLC boosted its holdings in Neurocrine Biosciences by 4.5% during the fourth quarter. Teza Capital Management LLC now owns 17,864 shares of the company’s stock valued at $2,438,000 after acquiring an additional 765 shares during the period. Finally, Strategic Global Advisors LLC boosted its holdings in Neurocrine Biosciences by 4.2% during the fourth quarter. Strategic Global Advisors LLC now owns 20,521 shares of the company’s stock valued at $2,801,000 after acquiring an additional 827 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $122.82 on Tuesday. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The firm has a market capitalization of $12.16 billion, a P/E ratio of 37.33, a P/E/G ratio of 0.77 and a beta of 0.26. The company’s 50 day simple moving average is $107.30 and its 200 day simple moving average is $121.93.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. During the same period last year, the company earned $1.20 EPS. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. Sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences declared that its Board of Directors has authorized a share repurchase program on Friday, February 21st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at Neurocrine Biosciences

In related news, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director now owns 37,491 shares of the company’s stock, valued at $4,131,508.20. This trade represents a 44.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NBIX shares. BMO Capital Markets upped their price target on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the company a “market perform” rating in a report on Tuesday, May 6th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 20th. Bank of America decreased their price target on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating for the company in a report on Friday, February 7th. Canaccord Genuity Group upped their price target on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, May 6th. Finally, UBS Group increased their target price on shares of Neurocrine Biosciences from $137.00 to $152.00 and gave the company a “buy” rating in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $162.00.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.